NCT00102492
Completed
Phase 2
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Depressive Disorder, Major
- Sponsor
- GlaxoSmithKline
- Enrollment
- 356
- Locations
- 1
- Primary Endpoint
- Change from baseline on the 17-item Hamilton Depression Rating Scale (HAM-D) total score at week 8, Last Observation Carried Forward.
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Change from baseline on the 17-item Hamilton Depression Rating Scale (HAM-D) total score at week 8, Last Observation Carried Forward.
Secondary Outcomes
- CGI, HAM-A, QUIDS, SDS, MOS-12 Sleep Module, LSEQ, Safety and Tolerability, PK/PD
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a PlaceboDermatitis, AtopicNCT01299610GlaxoSmithKline25
Completed
Phase 1
A Study Assessing GW870086's Potential to Cause Skin ThinningDermatitis, AtopicNCT01381445GlaxoSmithKline20
Completed
Phase 2
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary InsomniaSleep Initiation and Maintenance DisordersInsomniaNCT00354809GlaxoSmithKline68
Completed
Phase 3
Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With ObesityObesityNCT03842501Golo68
Completed
Phase 2
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C SubjectsCirrhosis, LiverNCT00244751GlaxoSmithKline265